These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 24682973)
1. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973 [TBL] [Abstract][Full Text] [Related]
2. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis. Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217 [TBL] [Abstract][Full Text] [Related]
3. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage. Romme Christensen J; Komori M; von Essen MR; Ratzer R; Börnsen L; Bielekova B; Sellebjerg F Mult Scler; 2019 Jun; 25(7):937-946. PubMed ID: 29775134 [TBL] [Abstract][Full Text] [Related]
4. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691 [TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A Mult Scler; 2014 Jan; 20(1):43-50. PubMed ID: 23702432 [TBL] [Abstract][Full Text] [Related]
7. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388 [TBL] [Abstract][Full Text] [Related]
8. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731 [TBL] [Abstract][Full Text] [Related]
9. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359 [TBL] [Abstract][Full Text] [Related]
10. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044 [TBL] [Abstract][Full Text] [Related]